A practical reference on preclinical model: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-11-26 and is reviewed periodically as new material appears.
Identity and purity are checked with standard peptide techniques. Reversed-phase high-performance liquid chromatography separates the main peak from closely related impurities and yields a percentage purity. Mass spectrometry confirms that the measured mass matches the theoretical value. Amino acid analysis offers an independent check on overall composition. These analytical methods characterize the material itself and reveal nothing about how it behaves in a living system.
In its common research form the peptide is supplied as a lyophilized powder. It dissolves readily in water and in typical aqueous buffers, which simplifies preparation of working solutions. Laboratories usually prepare small aliquots instead of one large volume. The dry material appears as a white to off-white solid with no distinctive odor. Bulk quantities are typically shipped in sealed vials.
Lyophilized material is generally kept cold, commonly at minus twenty degrees Celsius, and shielded from moisture and light. Solutions are less stable than the dry powder, so repeated freeze-thaw cycles are avoided by splitting the material into single-use portions. Published stability data for this particular peptide are limited, which means suggested hold times should be read as provisional. Long-term refrigeration of reconstituted solutions is not well supported by available evidence.
Interest in the peptide has grown through online communities that discuss self-administered use, which sits outside formal research settings. Regulatory status varies by country, and in many jurisdictions the compound is not approved as a therapeutic product. Questions about optimal routes of administration, long-term effects, and dose-response relationships remain open. Published pharmacokinetic data in humans are limited, and much of what circulates in popular discussion is extrapolated from animal work rather than measured directly in people.
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
Published work on BPC-157 spans several decades and covers a wide range of experimental models. Much of the early literature reports outcomes in animal studies involving induced injury to the gastrointestinal tract, tendons, and other tissues. The volume of preclinical reports is large, while controlled human trials remain scarce. This imbalance is a recurring point of discussion, because animal findings do not automatically translate into human effects. Reviews often note that study designs differ substantially across laboratories.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white lyophilized powder | Visual inspection of dry material |
| Solubility | Soluble in water | Polar aqueous solvent class |
| Typical storage | Minus 20 degrees Celsius, desiccated, dark | Applies to the lyophilized form |
| Purity assessment | Reversed-phase HPLC | Ultraviolet detection, area percent |
| Identity confirmation | Mass spectrometry | Measured mass compared with theoretical value |
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry using electrospray or MALDI ionisation. Amino acid analysis and peptide mapping by enzymatic digestion provide additional sequence-level confirmation. Purity is commonly reported as an area percentage from a chromatographic trace, and water content can be measured by Karl Fischer titration. Reported masses may differ by tens of daltons between sources because preparations can contain acetate or trifluoroacetate counterions, and such differences are not by themselves evidence of a different peptide.
BPC-157 is normally distributed as a lyophilised powder that ranges from white to off-white in appearance. The peptide dissolves readily in water, normal saline, and common aqueous buffers, and it is poorly soluble in nonpolar solvents such as hexane or vegetable oils. Lyophilised vials take up moisture if left open, which changes the mass of powder in the container and complicates any later weighing. Because the material is handled in small quantities, static and adhesion to glass or plastic can also cause noticeable losses during transfer.
The main chemical liabilities of this sequence are peptide-bond hydrolysis and possible aspartate-related reactions, since the peptide contains aspartic acid residues but no cysteine, methionine, or tryptophan. Absence of those three residues removes the most common oxidation and disulfide pathways from consideration. Studies of related peptides indicate that aspartate isomerisation and aspartimide formation occur most readily at Asp-Gly and Asp-Ala positions, and open questions remain about how quickly those reactions proceed under ordinary laboratory conditions. Storage guidance typically emphasises cool, dry, dark conditions to slow hydrolysis.
Several mechanisms have been proposed to explain the activity observed in animal models. The most frequently cited involve signaling through vascular endothelial growth factor receptor 2 and modulation of the nitric oxide system. Researchers have also described interactions with protective pathways in the gut lining. These proposed mechanisms appear in the literature as hypotheses supported by preclinical observations, not as confirmed pathways in humans. The precise way the peptide produces its reported effects, and whether those effects carry across species, remain areas of active and unresolved investigation.
BPC-157 is a synthetic pentadecapeptide, meaning it consists of fifteen amino acids joined in a single chain. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a fragment corresponding to part of a larger protein found in human gastric juice. The peptide was first described in the 1990s by researchers in Zagreb who were studying gastric protective factors. It is not a naturally circulating hormone; it is a laboratory-made fragment derived from a stomach protein. The name is an abbreviation of body protection compound, with the number referring to the fragment's position in the source protein.
Most published work on BPC-157 comes from animal experiments rather than controlled human trials. Rodent models have examined its effects on gastrointestinal lesions, tendon and ligament injury, and blood vessel formation. These studies are often small and originate from a limited number of research groups, which affects how broadly the findings can be generalized. No large randomized human trial has been reported in the peer-reviewed literature. Discussion of the compound therefore rests largely on preclinical data, and questions about its effects in people remain open rather than settled.
Some properties, such as the peptide's sequence and molecular mass, are firmly established. Other claims, particularly about mechanism and clinical benefit, remain open questions. Proposed mechanisms include effects on nitric oxide signaling and on cell migration, but these are hypotheses supported by limited evidence. Reviewers often note that the field lacks large controlled human trials. Positive animal findings are best treated as signals for further study rather than as settled conclusions.
Most published studies examine BPC-157 in animal models rather than in humans. Common subjects include rats and mice, and researchers often use models of tissue injury, surgery, or induced inflammation. Reported endpoints include healing rates, blood vessel formation, and markers of tissue repair. These designs provide controlled comparisons, but findings in animals do not automatically transfer to people. Human clinical data remain limited and are frequently described as preliminary.
Doses in the literature are usually expressed in micrograms or nanograms per kilogram of body weight. Investigators have administered the peptide by several routes, including injection and oral delivery, depending on the question asked. Route and dose vary widely across studies, which complicates direct comparison of results. Many papers report effects at low doses, but the absence of a standardized protocol limits generalization. Reporting practice differs between research groups.
Published storage guidance follows general peptide practice rather than product-specific studies. The dry powder is typically kept at minus 20 degrees Celsius, away from light and moisture. Once reconstituted, solutions are generally refrigerated and used over days to weeks, because the aqueous environment slowly promotes hydrolysis and oxidation. Long-term data on degradation rates or breakdown products are sparse. Stated shelf lives from different producers vary widely, reflecting the absence of a shared reference standard.
BPC-157 is a synthetic peptide built from fifteen amino acid residues. Its sequence comes from a larger protein fragment that researchers isolated from human gastric juice and described as a body protection compound. The fragment contains glycine, glutamic acid, five prolines, lysine, alanine, two aspartic acids, leucine, and valine. The number 157 in the name refers to the position of the stretch within the parent protein. Material used in laboratories is manufactured rather than extracted from stomach fluid.
The molecule carries 15 residues, a molar mass near 1419.5 g/mol, and the formula C62H98N16O22. Its structure features a proline-rich central region, a pair of adjacent aspartic acid residues, and no cysteine. The absence of cysteine means no disulfide bonds can form, which simplifies refolding and reconstitution. Suppliers usually ship the material as a freeze-dried powder that appears white to off-white. It dissolves readily in water and in saline solutions.
JINR did not propose a name after their first report claiming synthesis of element 105, which would have been the usual practice. This led LBL to believe that JINR did not have enough experimental data to back their claim. After collecting more data, JINR proposed the name bohrium (Bo) in honor of the Danish nuclear physicist Niels Bohr, a founder of the theories of atomic structure and quantum theory; they soon changed their proposal to nielsbohrium (Ns) to avoid confusion with boron. Another proposed name was dubnium. When LBL first announced their synthesis of element 105, they proposed that the new element be named hahnium (Ha) after the German chemist Otto Hahn, the "father of nuclear chemistry", thus creating an element naming controversy. In the early 1970s, both teams reported synthesis of the next element, element 106, but did not suggest names. JINR suggested establishing an international committee to clarify the discovery criteria. This proposal was accepted in 1974 and a neutral joint group formed. Neither team showed interest in resolving the conflict through a third party, so the leading scientists of LBL—Albert Ghiorso and Glenn Seaborg—traveled to Dubna in 1975 and met with the leading scientists of JINR—Georgy Flerov, Yuri Oganessian, and others—to try to resolve the conflict internally and render the neutral joint group unnecessary; after two hours of discussions, this failed. The joint neutral group never assembled to assess the claims, and the conflict remained unresolved.
=== Project REWARD === The REWARD (Real time wide area radiation surveillance system) project was established to address the threats of nuclear terrorism, missing radioactive sources, radioactive contamination and nuclear accidents. The consortium developed a mobile system for real time wide area radiation monitoring based on the integration of new miniaturized solid state sensors. Two sensors are used: a cadmium zinc telluride (CdZnTe) detector for gamma radiation and a high efficiency neutron detector based on novel silicon technologies. The gamma and neutron detectors are integrated into a single monitoring device called a tag. The sensor unit includes a wireless communication interface to remotely transmit data to a monitoring base station, which also uses a GPS system to calculate the tag's position.
In some archaea, i.e. members of the Methanobacteriales and in the genus Methanopyrus, pseudopeptidoglycan (pseudomurein) has been found. In pseudopeptidoglycan the sugar residues are β-(1,3) linked N-acetylglucosamine and N-acetyltalosaminuronic acid. This makes the cell walls of such archaea insensitive to lysozyme. The biosynthesis of pseudopeptidoglycan has been described.
== Medical uses == Paroxetine is primarily used to treat major depressive disorder, obsessive–compulsive disorder, post-traumatic stress disorder, social anxiety disorder, and panic disorder. It is also occasionally used for agoraphobia, generalized anxiety disorder, premenstrual dysphoric disorder, and menopausal hot flashes.
== January 11, 1982 (Monday) == The lowest temperature ever recorded in England was measured at Newport, Shropshire, where the thermometer reading was −26.1 °C (−15.0 °F). Filming began on Return of the Jedi, the third film in the Star Wars franchise, and the conclusion of the original trilogy, with production starting at sound stages the Elstree Studios in England at Borehamwood, Hertfordshire. Born: Denis Kolodin, Russian footballer with 23 caps for the Russia national team; in Kamyshin, Russian SFSR, Soviet Union Blake Heron, American actor known for his starring role in the 1996 film Shiloh; in Rockville Centre, New York (d. from a drug overdose, 2017) Died: Jiro Horikoshi, Japanese aeronautical engineer who designed the Zero fighter. A. W. Haydon, 75, American inventor wand specialist in miniaturization, known for his invention of 82 devices and innovations, including the microswitch used in computers, as well other devices for use by the general public, by the U.S. military and by NASA Sir Kenneth Strong, 81, British Army Major General and advisor of the Normandy Landings on D-Day in 1944, as well as negotiating the surrender of both Italy and Japan Carl M. Voyles, 83, American Canadian football head coach for the Hamilton Tiger-Cats, known for guiding the team to winning the 1953 Grey Cup Manya Surve, 37, Indian gangster, suspected in multiple murders and robberies, became the first of 622 criminals in Bombay to die in an "encounter killing" by police in the Maharashtra state.
Sources: en.wikipedia.org
=== Labor relations === In 2010, when the Industrial Workers of the World attempted to unionize ten Minneapolis locations, The New York Times called the effort "one of the few efforts to organize fast-food workers in American history". In July 2017, the United States Court of Appeals for the Eighth Circuit found that the National Labor Relations Act did not protect Jimmy John's employees from being fired for exhibiting legally disloyal conduct by attacking the company's product to oppose a franchisee's sick leave policy. In October 2014, it was revealed that employees at Jimmy John's, including sandwich makers and delivery drivers, were required to sign non-compete agreements as a condition of employment. The agreement restricted the employee from working for a competitor for two years, where a competitor was defined as a business that derives more than ten percent of its revenue from selling sandwiches and is located within three miles of any Jimmy John's. Additionally, the employee could not work for another Jimmy John's franchisee for a year. Jimmy John's has since settled related lawsuits filed by the Attorneys General of New York and Illinois. In statements, the company clarified that it had taken steps to remove non-compete agreements from their new hire paperwork long before they were contacted by the Attorneys General, and that "enforcement of non-compete agreements against our own hourly store employees is not a part of Jimmy John's culture or business model."
In an interview to Italian newspaper Corriere della Sera on 20 June, Lula asserted that Italy is a priority for Brazil, especially because Brazil has "30 million Brazilians of Italian descent and great relations with Italian trade unions, intellectuals and companies". On 20 June, Lula met with left-wing sociologist and professor emeritus at the Sapienza University of Rome Domenico De Masi during his visit to Rome. On 21 June, Lula met with General Secretary of the Democratic Party (PD), Elly Schlein, and former Prime Minister Massimo D'Alema, with whom he reportedly had talks about "democracy, world peace, climate change, inequality and challenges common to several countries". Brazilian government officials also said that Lula and Schlein had a talk about "gender violence and sexism in politics". Lula also met and dined with Italian president Sergio Mattarella at the Quirinal Palace to reportedly discuss about the relations between Brazil and Italy, as well as the Mercosur-European Union deal. Upon returning from his visit to the Vatican, he also had a meeting with Italian Prime Minister Giorgia Meloni at the Chigi Palace. During an interview to the press after the meeting, he praised Meloni, saying that "ideological differences wouldn't end diplomacy" between the two countries. Lula also had a meeting and private dinner with Rome mayor Roberto Gualtieri.
== Function and location == The OXTR protein belongs to the G protein-coupled receptor (GPCR) family, specifically Gq, and acts as a receptor for oxytocin. Its activity is mediated by G proteins that activate several different second messenger systems. Oxytocin receptors are expressed by the myoepithelial cells of the mammary gland, and in both the myometrium and endometrium of the uterus at the end of pregnancy. The oxytocin receptor system plays an important role as an inducer of uterine contractions during parturition and of milk ejection. OXTR is also associated with the central nervous system. The gene is believed to play a major role in social, cognitive, and emotional behavior. A decrease in OXTR expression by methylation of the OXTR gene is associated with callous and unemotional traits in adolescence, rigid thinking in anorexia nervosa, problems with facial and emotional recognition, and difficulties in the affect regulation. A reduction in this gene is believed to lead to prenatal stress, postnatal depression, and social anxiety. Studies on OXTR methylation—which downregulates oxytocin mechanisms—suggest this process is associated with increased gray matter density in the amygdala, implicating OXTR regulation in stress and parasympathetic regulation. Social isolation has been found to decrease oxytocin receptor levels in rodents, whereas levels of oxytocin were unchanged.
== History == Amanita muscaria has been used by humans as a psychoactive drug since ancient times. Muscimol was isolated from Amanita muscaria independently by three different research groups in 1964 and 1965. It was synthesized by Gagneux and colleagues in 1965. The chemical structure of muscimol, along with that of ibotenic acid, was published by Conrad Eugster at the University of Zurich in 1967. Its structural similarity to the neurotransmitter γ-aminobutyric acid (GABA) was quickly recognized and muscimol was shown to have GABA-like actions by Graham Johnston and colleagues in 1968. Subsequently, its actions were shown to be reversed by the GABA receptor antagonist bicuculline in 1971. The effects of muscimol in humans were studied and described by Waser in 1967. Later, ethnobotanist Jonathan Ott further described the effects of muscimol, via Amanita pantherina consumption, in 1976. Danish medicinal chemist Povl Krogsgaard-Larsen and colleagues studied muscimol and synthetic analogues over several decades starting in the 1970s. Other GABAA receptor ligands, such as gaboxadol (THIP) and 4-PIOL, and GABA transporter modulators, such as nipecotic acid and tiagabine, have been derived from muscimol. Many muscimol analogues were developed by Krogsgaard-Larsen and colleagues. Muscimol was encountered online as a novel designer drug in 2023.
=== Betaines and similar compounds === The compound trimethylglycine, named as "betaine", contain the same structural motif, a quaternary nitrogen atom with a carboxylate group attached to it via a –CH2– link. All compounds whose structure includes this motif are known as betaines. Betaines do not isomerize because the chemical groups attached to the nitrogen atom are not labile. These compounds may be classed as permanent zwitterions, as isomerisation to a molecule with no electrical charges does not occur, or is very slow. Other examples of permanent zwitterions include phosphatidylcholines, which also contain a quaternary nitrogen atom, but with a negatively-charged phosphate group in place of a carboxylate group; sulfobetaines, which contain a quaternary nitrogen atom and a negatively charged sulfonate group; and pulmonary surfactants such as dipalmitoylphosphatidylcholine. Lauramidopropyl betaine is the major component of cocamidopropyl betaine.
Sources: en.wikipedia.org
Dry powder is commonly held at minus twenty degrees Celsius, desiccated and away from light. Cold storage slows degradation of the lyophilized material.
Mass spectrometry establishes the molecular mass, and reversed-phase chromatography reports purity. A certificate of analysis typically combines both results.
Solutions degrade faster than the dry powder, particularly at room temperature. Portioning into single-use aliquots and freezing reduces losses from repeated thawing.
It is a synthetic peptide of fifteen amino acids whose sequence matches a fragment of a protein found in human gastric juice. It is studied mainly in laboratory and animal research rather than as an approved medicine.